Relationship Between Healthcare Spending and Life Expectancy
Case Scenario: Launching a Cancer Drug: Comanapracil
You are a pharmaceutical executive and you are preparing a presentation for a Board of Directors. You believe that your firm, Ropache, may have developed a promising new drug, Comanapracil, which seems to arrest the progress of breast cancer for 2 years with no significant side effects. Clinical trials suggest that the drug is 100% effective for 2 years. After 2 years, tumor growth resumes at the same rate. Therefore, Comanapracil can only be used for a 2-year course, after which it loses its effectiveness.
QUESTION.
Create a brief draft slide presentation of your market analysis including speaker’s notes addressing the following:
- Explain the relationship between spending on healthcare per capital and the life expectancy in Germany, the United States, Ghana, and Brazil and whether there is a relationship between life expectancy and healthcare spending.
- Summarize the structure of each country’s healthcare system.
- Describe the results of your SWOT analysis for marketing the drug in each country.
Recommend to countries you determined to be most attractive for marketing Comanapracil and explain why they are attractive marketing the drug.
- Describe how you would explain to the IQWIG (Institute for Quality and Efficiency in Health Care) how much gain in health outcomes the drug will provide, whether other drugs provide similar effectiveness in treating breast cancer, and how people will benefit from the drug including why some will benefit more from the drug more than others.
Case Scenario Analysis
Student’s Name
College/University
Course
Professor’s Name
Due Date
Relationship Between Healthcare Spending and Life Expectancy
There is an intricate relationship between life expectancy and healthcare expenditure, subject to variations depending on the country. It is, therefore, vital to understand such associations in countries like Germany, the United States, Ghana, and Brazil.
Germany
Germany experiences more healthcare spending per capita and has a well-advanced healthcare system with private and public providers. This healthcare investment threshold and the country’s focus on universal access, early intervention, and preventive care have helped augment citizens’ life expectancy (Achstetter et al., 2022).
The United States
The United States leads in healthcare expenditure per capita globally, although it has a lower life expectancy than other developed countries (Schwartz & Woloshin, 2019). The country’s healthcare system incorporates public and private providers; thus, income and insurance coverage affect healthcare access. While the country has robust medical treatments and technologies, access and care quality inequalities impact life expectancy.
Ghana
Healthcare spending per capita in the country is lower than in developed countries like the United States and Germany. Ghana’s healthcare system experiences challenges regarding healthcare services access, infrastructure, and resources, which can affect health outcomes (Christmals & Aidam, 2020).
Brazil
Brazil has higher healthcare spending per capita than Ghana but is lower than the United States and Germany. The country’s healthcare system has private and public healthcare providers, with private health expenditures exceeding public expenditures (Castro et al., 2019). Regional differences and socioeconomic inequalities in healthcare quality and access can affect Brazil’s life expectancy.
Healthcare System Structure Summary
Germany has a universal healthcare system with private and public providers (Achstetter et al., 2022). Although insurance coverage differs, the United States healthcare system entails public and private providers. Ghana’s healthcare system has private and public providers and experiences significant resource constraints (Christmals & Aidam, 2020). Brazil has a mixed healthcare system with substantial healthcare quality and access inequalities.
SWOT Analysis for Comanapracil Marketing
Germany
Germany has greater healthcare spending, and its focus on early intervention presents strengths (Achstetter et al., 2022). However, the potential pricing challenges due to stringent cost-effectiveness assessments present weaknesses. The country has high market demand for robust breast cancer treatment. The competition from other existing breast cancer drugs is a threat.
The United States
The strengths lie in the country’s large pharmaceuticals market and increased healthcare spending. The sophisticated healthcare reimbursement systems and cost considerations present weaknesses. The increased demand for innovative cancer treatments offers opportunities but extreme competition...